Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock March 29, 2017 • 4:07 PM EDT
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference March 29, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL March 28, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference March 15, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL March 14, 2017 • 7:00 AM EDT
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 29th Annual ROTH Conference March 7, 2017 • 7:00 AM EST
Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus March 2, 2017 • 7:24 AM EST
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference February 28, 2017 • 7:00 AM EST
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference February 9, 2017 • 7:00 AM EST
